Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 2Solid Tumor 2Refractory or Relapsed Solid Tumors 1Prostate Cancer Recurrent 1Malignant Solid Tumour 1Bone Metastases 1

Interventions

Irinotecan 31Paclitaxel 27Gemcitabine 27Cisplatin 25Docetaxel 20Oxaliplatin 16Fluorouracil 15alvocidib 13Leucovorin 13Carboplatin 13Capecitabine 12Bortezomib 10Early Intervention, Educational 9Topotecan 8Taxes 8Bevacizumab 73-aminopyridine-2-carboxaldehyde thiosemicarbazone 7ixabepilone 6Vorinostat 6Temozolomide 6Sorafenib 6Immunohistochemistry 6Immunoenzyme Techniques 67-hydroxystaurosporine 6tanespimycin 5Pharmacogenomic Testing 5Pemetrexed 5Magnetic Resonance Spectroscopy 5Filgrastim 5Etoposide 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unspecified Adult Solid Tumor, Protocol Specific × Hydroxychloroquine × Other solid neoplasm × Clear all
NCT00909831 2019-04-16

Hydroxychloroquine and Temsirolimus in Treating Patients With Metastatic Solid Tumors That Have Not Responded to Treatment

Abramson Cancer Center at Penn Medicine

Phase 1 Completed
40 enrolled
Other solid neoplasm

Unspecified Adult Solid Tumor, Protocol Specific

NCT00714181 2016-02-18

Hydroxychloroquine and Temozolomide in Treating Patients With Metastatic or Unresectable Solid Tumors

Abramson Cancer Center at Penn Medicine

Phase 1 Completed
38 enrolled
Other solid neoplasm

Unspecified Adult Solid Tumor, Protocol Specific

Data powered by HemOnc (CC BY 4.0) Colophon âš¡